Cardiff Oncology, Inc.
CRDFNext catalyst
Onvansertib
Colorectal Cancer
Get an email about CRDF's next catalysts
Track Cardiff Oncology (CRDF) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 1 past
Onvansertib Phase 2 Est. Readout
Estimated primary completion for Onvansertib trial (NCT05383196) in Breast Cancer. Topline data typically follows completion by weeks to months.
SourceOnvansertib Phase 2 Est. Readout
Estimated primary completion for Onvansertib trial (NCT05383196) in Breast Cancer. Topline data typically follows completion by weeks to months.
SourceOnvansertib Phase 2 Est. Readout
Estimated primary completion for Onvansertib trial (NCT05450965) in Small-cell Lung Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Onvansertib
Colorectal Cancer
Nanoliposomal irinotecan
Pancreatic Ductal Adenocarcinoma
NALIRIFOX
Pancreatic Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Onvansertib | Phase 2 | Colorectal Cancer | - | - |
Nanoliposomal irinotecan | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
NALIRIFOX | Phase 2 | Pancreatic Cancer | - | - |
Frequently asked questions
What is in Cardiff Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cardiff Oncology, Inc.'s (CRDF) pipeline across Phase 2. Its lead program is Onvansertib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cardiff Oncology, Inc.'s next FDA catalyst?→
Cardiff Oncology, Inc.'s (CRDF) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRDF biotech catalysts?→
Add CRDF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cardiff Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.